問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
陳芝蓉
下載
2024-07-31 - 2031-12-31
Condition/Disease
BRCA1, BRCA2 or PALB2 Mutations and Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
Test Drug
tablets tablets
Participate Sites7Sites
Recruiting7Sites
2022-04-01 - 2026-03-31
Participate Sites8Sites
Recruiting8Sites
2020-07-01 - 2027-12-31
HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting
Trastuzumab deruxtecan (ENHERTUR)
2014-05-01 - 2029-12-31
Participate Sites6Sites
Recruiting6Sites
2021-11-01 - 2026-12-31
2023-10-01 - 2033-02-05
Breast Cancer
Datopotamab deruxtecanDurvalumab
2021-09-22 - 2033-12-31
Participate Sites14Sites
Recruiting14Sites
2019-01-01 - 2026-06-30
Participate Sites9Sites
Recruiting9Sites
2016-12-29 - 2023-09-28
Hormone Receptor-Positive Advanced Breast Cancer
NA
Terminated2Sites
Division of Hematology & Oncology
未分科
2023-08-01 - 2036-12-31
全部
